Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: Soluble forms in relation to tumor tissue expression and metastasis

Journal of Gastrointestinal Cancer

Volumn 39, Issue 1-4, 2008, Pages 73-78

  Amirghofran, Zahra ^a,b   Jalali, Seyed Amir ^a   Hosseini, Seyed Vahid ^c   Vasei, Mohammad ^d   Sabayan, Behnam ^c   Ghaderi, Abbas ^a,e  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD44; CD44v6; Colorectal cancer

Indexed keywords

CD44V6 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; BLOOD; CHEMISTRY; COLORECTAL TUMOR; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD44; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69849092028     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-009-9062-2     Document Type: Article

References (27)

1. SV Hosseini A Izadpanah H Yarmohammadi 2004 Epidemiological changes in colorectal cancer in Shiraz, Iran:1980-2000 ANZ J Surg 74 547 549 15230787 10.1111/j.1445-2197.2004.03064.x (Pubitemid 39006075)
2. FW Orr HH Wang 2001 Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis Surg Oncol Clin N Am 10 357 381 11382592 1:STN:280:DC%2BD3M3ps1eitA%3D%3D
3. M Iiizumi S Mohinta S Bandyopadhyay, et al. 2007 Tumor-endothelial cell interactions: therapeutic potential Microvasc Res 74 114 120 17498748 10.1016/j.mvr.2007.04.002 1:CAS:528:DC%2BD2sXht1ykur7O (Pubitemid 350051022)
4. R Dalchau J Kirkley JW Fabre 1980 Monoclonal anti-body to a human leukocyte-specific membrane glyco-protein probably homologous to the leukocyte-common (L-C) antigen of the rat Eur J Immunol 10 737 744 7428806 10.1002/eji.1830101003 1:CAS:528:DyaL3MXhtlyrsw%3D%3D
5. U Dianzani F Malavasi 1995 Lymphocyte adhesion to endothelium Crit Rev Immunol 15 167 200 8573287 1:CAS:528:DyaK28XkslartA%3D%3D
6. GR Screaton MV Bell DG Jackson, et al. 1992 Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons Proc Natl Acad Sci USA 89 12160 12464 1465456 10.1073/pnas.89.24. 12160 1:CAS:528:DyaK3sXhvVCrsLc%3D (Pubitemid 23004805)
7. U Günthert M Hofmann W Rudy, et al. 1991 A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 13 24 1707342 10.1016/0092-8674(91)90403-L
8. N Iida LYW Bourguignon 1995 New CD44 splice variants associated with human breast cancers J Cell Physiol 162 127 133 7529235 10.1002/jcp.1041620115 1:CAS:528:DyaK2MXivFaqtbc%3D
9. E Manten-Horst EH Danen L Smit, et al. 1995 Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential Int J Cancer Pred Oncol 64 182 188 10.1002/ijc.2910640307 1:CAS:528:DyaK2MXnt1Cit7w%3D
10. LJ Picker J De Los Toyos MJ Telen, et al. 1989 Monoclonal antibodies against the CD44 [in(lu)-related p80] and pgp-1 antigens in man recognize the Hermes class of lymphocyte homing receptors J Immunol 142 2046 2051 2646376 1:CAS:528:DyaL1MXhslWgu7w%3D
11. V Bazil B Horejsi 1992 Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand J Immunol 149 747 753 1634766 1:CAS:528: DyaK38XmsV2lt7Y%3D
12. R Ristamäki H Joensuu S Jalkanen 1996 Does soluble CD44 reflect the clinical behavior of human cancer? Curr Top Microbiol Immunol 213 155 166 8815003 (Pubitemid 26165101)
13. F Gansauge S Gansauge B Rau, et al. 1997 Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma Cancer 80 1733 1739 9351541 10.1002/(SICI)1097- 0142(19971101)80:9<1733::AID-CNCR6>3.0.CO;2-F 1:STN:280: DyaK1c%2FhtF2jtA%3D%3D (Pubitemid 27475930)
14. V Subramaniam H Gardner S Jothy 2007 Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells Exp Molecular Pathol 83 341 346 10.1016/j.yexmp.2007.08.007 1:CAS:528: DC%2BD2sXhtlagsb%2FM (Pubitemid 350087028)
15. J Cichy E Pure 2003 The liberation of CD44 J Cell Biol 161 839 843 12796473 10.1083/jcb.200302098 1:CAS:528:DC%2BD3sXks1Gmu7g%3D (Pubitemid 36718417)
16. M Andratschke S Chaubal C Pauli, et al. 2005 Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer Anticancer Res 25 2821 2826 16080532 1:CAS:528:DC%2BD2MXpt1WrsL4%3D
17. M Lein K Jung S Weiss, et al. 1997 Soluble CD44 variants in the serum of patients with urological malignancies Oncology 54 226 230 9143404 1:STN:280:DyaK2s3ovVChtA%3D%3D 10.1159/000227693
18. C Kainz C Tempfer S Winkler, et al. 1995 Serum CD44 splice variants in cervical cancer patients Cancer Lett 90 231 234 7537626 10.1016/0304-3835(95) 03708-5 1:CAS:528:DyaK2MXlt1Sqtbc%3D
19. K Jung M Lein S Weiss, et al. 1996 Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia Eur J Cancer 32A 627 630 8695265 10.1016/0959-8049(95)00634-6 1:STN:280:DyaK283ntlGgug%3D%3D
20. D Masson MG Denis M Denis, et al. 1999 Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer Br J Cancer 80 1995 2000 10471052 10.1038/sj.bjc.6690633 1:CAS:528:DyaK1MXlvVais70%3D (Pubitemid 29391287)
21. B Zalewski 2004 Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features World J Gastroenterol 10 583 585 14966921 1:CAS:528:DC%2BD2cXislalurk%3D
22. S Weg-Remers U Hildebrandt G Feifel, et al. 1998 Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6 Am J Gastroenterol 93 790 794 9625129 10.1111/j.1572-0241.1998.226-a.x 1:CAS:528:DyaK1cXmt1Grsb4%3D (Pubitemid 29063923)
23. N Yamane S Tsujitani M Makino, et al. 1999 Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal Cancer Oncology 56 232 238 10202279 10.1159/000011970 1:CAS:528:DyaK1MXisFGhtr8%3D
24. J Perez-Palma J Marchena-Gomez M Dorta-Espineira, et al. 2008 Predictive factors of years of potential life lost by colorectal cancer Eur J Gastroenterol Hepatol 20 766 772 18617781 10.1097/MEG.0b013e3282fbf5d3
25. SK Mai G Welzel B Hermann, et al. 2008 Long-term outcome after combined radiochemotherapy for anal cancer-retrospective analysis of efficacy, prognostic factors, and toxicity Onkologie 31 251 257 18497514 10.1159/000121362 (Pubitemid 351744825)
26. R Bendardaf A Algars A Elzagheid, et al. 2006 Comparison of CD44 expression in primary tumours and metastases of colorectal cancer Oncol Rep 16 741 746 16969488 1:CAS:528:DC%2BD28XhtFSisrzL
27. JC Zhang ZR Wang YJ Cheng, et al. 2003 Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D World J Gastroenterol 9 1482 1486 12854146